These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 25768255

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. PREVALENCE OF MYD88 L265P MUTATION IN HISTOLOGICALLY PROVEN, DIFFUSE LARGE B-CELL VITREORETINAL LYMPHOMA.
    Raja H, Salomão DR, Viswanatha DS, Pulido JS.
    Retina; 2016 Mar; 36(3):624-8. PubMed ID: 26900675
    [Abstract] [Full Text] [Related]

  • 3. Clinical Relevance of the High Prevalence of MYD88 L265P Mutated Vitreoretinal Lymphoma Identified by Droplet Digital Polymerase Chain Reaction.
    Shi H, Zhou X, Chen B, Xiao J, Li Y, Zhou X, Zhou Q, Chen K, Wang Q.
    Ocul Immunol Inflamm; 2021 Apr 03; 29(3):448-455. PubMed ID: 31603365
    [Abstract] [Full Text] [Related]

  • 4. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
    Choi JW, Kim Y, Lee JH, Kim YS.
    Hum Pathol; 2013 Jul 03; 44(7):1375-81. PubMed ID: 23380077
    [Abstract] [Full Text] [Related]

  • 5. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
    Cani AK, Hovelson DH, Demirci H, Johnson MW, Tomlins SA, Rao RC.
    Oncotarget; 2017 Jan 31; 8(5):7989-7998. PubMed ID: 28002793
    [Abstract] [Full Text] [Related]

  • 6. Clinical spectrum of vitreoretinal lymphoma and its association with MyD88 L265P mutation.
    Carreno E, Clench T, Steeples LR, Salvatore S, Lee RWJ, Dick AD, Pawade J.
    Acta Ophthalmol; 2019 Feb 31; 97(1):e138-e139. PubMed ID: 30113125
    [No Abstract] [Full Text] [Related]

  • 7. Single B-Cell Genomic Analyses Differentiate Vitreoretinal Lymphoma from Chronic Inflammation.
    Tan WJ, Wang MM, Castagnoli PR, Tang T, Chan ASY, Lim TS.
    Ophthalmology; 2021 Jul 31; 128(7):1079-1090. PubMed ID: 33221324
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. MYD88 L265P MUTATION DETECTION IN THE AQUEOUS HUMOR OF PATIENTS WITH VITREORETINAL LYMPHOMA.
    Miserocchi E, Ferreri AJM, Giuffrè C, Cangi MG, Francaviglia I, Calimeri T, Ponzoni M, Pecciarini L, Bandello FM, Modorati GM.
    Retina; 2019 Apr 31; 39(4):679-684. PubMed ID: 30204732
    [Abstract] [Full Text] [Related]

  • 10. Aqueous Humor-Derived MYD88 L265P Mutation Analysis in Vitreoretinal Lymphoma: A Potential Less Invasive Method for Diagnosis and Treatment Response Assessment.
    Demirci H, Rao RC, Elner VM, Demirci FY, Axenov L, Betz B, Behdad A, Brown N.
    Ophthalmol Retina; 2023 Feb 31; 7(2):189-195. PubMed ID: 35952929
    [Abstract] [Full Text] [Related]

  • 11. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
    Taniguchi K, Takata K, Chuang SS, Miyata-Takata T, Sato Y, Satou A, Hashimoto Y, Tamura M, Nagakita K, Ohnishi N, Noujima-Harada M, Tabata T, Kikuti YY, Maeda Y, Nakamura N, Tanimoto M, Yoshino T.
    Am J Surg Pathol; 2016 Mar 31; 40(3):324-34. PubMed ID: 26752547
    [Abstract] [Full Text] [Related]

  • 12. Vitreoretinal large B- cell lymphoma (VR- LBCL): Clinical and pathological features and treatment outcomes.
    Fadlelseed H, Rhatigan M, Treacy M, Murphy C, O'Neill J, Kilmartin D, Kennedy S.
    Pathol Res Pract; 2024 Sep 31; 261():155500. PubMed ID: 39106590
    [Abstract] [Full Text] [Related]

  • 13. Vitreoretinal presentation of secondary large B-cell lymphoma in patients with systemic lymphoma.
    Salomão DR, Pulido JS, Johnston PB, Canal-Fontcuberta I, Feldman AL.
    JAMA Ophthalmol; 2013 Sep 31; 131(9):1151-8. PubMed ID: 23744124
    [Abstract] [Full Text] [Related]

  • 14. PreservCyt Is an Optimal Fixative that Permits Cytologic and Molecular Analyses of Vitreoretinal Lymphoma Biopsies.
    Wang MM, Tan WJ, Lim TS, Chan ASY.
    Ocul Immunol Inflamm; 2021 Apr 03; 29(3):430-439. PubMed ID: 31418635
    [Abstract] [Full Text] [Related]

  • 15. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.
    Pham-Ledard A, Beylot-Barry M, Barbe C, Leduc M, Petrella T, Vergier B, Martinez F, Cappellen D, Merlio JP, Grange F.
    JAMA Dermatol; 2014 Nov 03; 150(11):1173-9. PubMed ID: 25055137
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas.
    Caner V, Sen Turk N, Baris IC, Cetin GO, Tepeli E, Hacioglu S, Sari I, Zencir S, Dogu MH, Bagci G, Keskin A.
    Genet Test Mol Biomarkers; 2015 Jul 03; 19(7):372-8. PubMed ID: 25978699
    [Abstract] [Full Text] [Related]

  • 20. Allele-specific PCR is a powerful tool for the detection of the MYD88 L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples.
    Staiger AM, Ott MM, Parmentier S, Rosenwald A, Ott G, Horn H, Griese EU.
    Br J Haematol; 2015 Oct 03; 171(1):145-8. PubMed ID: 25816840
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.